Difference between revisions of "RhoA"
| Line 39: | Line 39: | ||
|- | |- | ||
| Surface accessibility | | Surface accessibility | ||
| − | | [http://gibk21.bse.kyutech.ac.jp/asaview/all/ | + | | [http://gibk21.bse.kyutech.ac.jp/asaview/all/1a2b.pdf ASAView] pdf |
| + | [http://gibk21.bse.kyutech.ac.jp/asaview/all/1a2b.txt ASAView] txt | ||
|- | |- | ||
| Disorder prediction | | Disorder prediction | ||
Revision as of 09:00, 25 July 2007
| Template:Infobox header| RhoA | |
|---|---|
| RhoA | |
| Substrate peptide name | RhoA |
| Synonyms | - |
| Determination type | In situ/In vitro |
| Source | Homo sapiens |
| Subcellular localization | Cytoskeleton |
| Swissprot ID | P61586 |
| Reactive glutamines | Q52, Q63, Q136 |
| Reactive lysines | - |
| Substrate sequence | EVDGKQVELAL
WDTAGQEDYDR LAKMKQEPVKP |
| Structure | 1A2B |
| Surface accessibility | ASAView pdf
ASAView txt |
| Disorder prediction | IUPred |
| Reference | PMID:9593707 |
| Notes | Q63 is deamidated/transamidated by TG2
The transamidated protein has increased binding affinity to ROCK-2. The deamidated form (by cytotoxic dermonecrotizing factor or BTX) has decreased GTPase activity. |
| Template:Infobox header | | |
